Company advanced its pipeline with initiation of Phase I/IIa GLIX1 trial in glioblastoma with promising preclinical data showing efficacy in temozolomide-resistant models. APHEXDA royalty revenues increased significantly YoY. Strong cash position extends runway into H1 2027. Management expressed confidence in recruitment and market opportunity ($3.7B addressable market). Stock price up 8.07% on the day.
Articles that tag BLRX but are mainly about other companies.
GLIX1 entered first-in-human Phase I/IIa trials in April 2026 through collaboration with Hemispherian, demonstrating progress in early-stage development.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
